WASHINGTON (Dow Jones)--The Food and Drug Administration said promotional material used by Allergan Inc. (AGN) violated agency rules. In a letter posted to FDA's website Monday, the agency said it had reviewed a direct mail item aimed at health-care professionals involving Lumigan, which is a prescription eye drop that treats glaucoma.
